🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the battle against drug-resistant strains of the pathogen, according to researchers.

An International Public Health Issue

Cases of gonorrhoea are on the rise around the world, with data suggesting in excess of 82 million infections annually. Notably increased rates are observed in Africa and countries within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the face of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted therapeutic options at this time.”

Public health authorities are particularly alarmed about the increase in treatment-resistant strains. The World Health Organization has listed it as a "priority pathogen". Ongoing monitoring found that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Receive Approval

Zoliflodacin, also known as Nuzolvence, was authorized by the US FDA in recent days for combating gonorrhoea. This disease can lead to major issues, including infertility. Experts hope that focused deployment of this new drug will help slow the development of resistance.

Gepotidacin, created by the drugmaker GSK, was also approved in close succession. This drug, which is additionally indicated for UTIs, was proven in research to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

Zoliflodacin emerged from a unique collaborative effort for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to bring it to fruition.

“This approval signifies a huge turning point in the treatment of highly resistant gonorrhoea, which until now has been outpacing medical innovation.”

Testing Outcomes and Worldwide Availability

Based on data detailed in a major medical journal, the new drug eradicated the vast majority of cases of the STI. This places it at an comparable level with the typical regimen, which involves an injection and a pill. The study involved nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the rights to license and sell the drug in numerous developing nations.

Clinicians on the front lines have expressed hope. Access to a single-dose, oral treatment of this kind is seen as a "revolutionary step" for public health efforts. This is viewed as essential to reduce the burden of the infection for patients and to stop the proliferation of highly drug-resistant gonorrhoea globally.